Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited third quarter 2023 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. If you have a question, please press the star key followed by the number one on your touchtone phone. If you would like to withdraw your question, please press the star two key followed by the number two on your touchtone phone. If you're using speaker equipment, please lift the handset before making your selection. This conference is being recorded today, November 15, 2023. I'd now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead. Thank you, and welcome everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the third quarter of 2023, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session. Also on our call today are Mr. Cameron Reynolds, President and Group Chief Executive Officer; Mr. Terig Hughes, Group Chief Financial Officer; Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary; and Dr. Andrew Retter, Medical Consultant to Volition. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used, based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. I would now like to turn the call over to our President and Group Chief Executive Officer, Mr. Cameron Reynolds. Cameron? Thanks, Scott, and thank you everyone for joining Volition's third quarter 2023 earnings call today. We especially appreciate your time, given this is the busy earnings call season. We will commence the call with a financial report from our Group Chief Financial Officer, Terig Hughes, before moving to Dr. Tom Butera, our Chief Executive Officer of Volition Veterinary, for an update on the rollout of our Nu.Q Vet Cancer Test. And then I'm delighted that Dr. Andy Retter, who works as a hematologist and intensive care consultant at one of the U.K.'s leading hospitals, has pre-recorded his thoughts on our progress in our Nu.Q NETs pillar, and in particular, the result of our FDA meeting, achieving a clear regulatory pathway, and also of our recent breakthrough early cancer detection method, recently presented at ESMO in October. I will wrap up with my thoughts on upcoming milestones and discuss our overall strategy going forward. Without further ado, I'll hand you across to Terig for the financial report. Terig? Thanks very much, Cameron, and thank you everyone for joining our earnings call today. I'll now provide a summary of the key financial results for the quarter ended September thirtieth, 2023. From a revenue perspective, we recorded revenue of $165,000 for the quarter, a fivefold increase over the same period last year. During the first three quarters of 2023, revenue grew 185% to $531,000. We believe that these results demonstrate steady growth, but not yet the ramp in revenues that we anticipate. We expect revenues to accelerate as we close out 2023 and into the early part of 2024, as several additional distributors come online with our Nu.Q Vet Test and our Nu.Q continues its growth. Year-on-year revenue growth was primarily driven by sales of the Nu.Q Vet Cancer Test, which grew almost fivefold over the nine-month period ended September 30th 2023, as compared to the prior year period, reflecting sales of the reference kits, mostly through our agreement with IDEXX, who we are working closely with on their marketing and expansion plans across the U.S. and into international markets. Revenue for Nu.Q Discover for the first three quarters of 2023 was $151,000, which reflects 38% growth over the comparative period in 2022. Looking ahead, as we have previously stated, it is difficult in these early stages of commercialization to provide meaningful revenue guidance. But as both Tom and Cameron will cover in their updates, we are pleased with the progress we are making across a number of our product pillars. We ended the quarter with cash and cash equivalents of approximately $10.8 million compared to $10.9 million at the end of 2022. Net cash used in operating activities during the quarter was approximately $8.4 million and included payments of almost $1 million related to our U.S. clinical trial activities in sepsis, which have since wound down due to successful completion of the first phase.... We are working hard to keep burn as low as possible while we commercialize a range of products, and more on that shortly. Total operating expenses for the quarter were $8.8 million, compared to $8 million for the third quarter of 2022. This increase was primarily the result of increased research and development expenditures, mainly reflecting the costs of our U.S. clinical trials, which added $0.7 million to the P&L costs in the quarter. Net loss for the quarter was $8.5 million, compared to $7.8 million for the three months ended September 30th 2022. As ever, and in particular, given the current macroeconomic conditions, we remain committed to careful expenditure and tight budget control. And to that end, we have recently completed a rationalization project and identified annualized savings of approximately $2 million, including a reduction in our overall headcount. It is a balance between investing in our product development and launches to ensure revenue growth and preserving precious capital. This is a balance we are very carefully and thoughtfully treading. To date, various European funding bodies, and in particular, Belgian agencies, have provided the company with approximately $19 million in non-dilutive funding in various forms, including cash grants or loans on favorable terms. This cash has helped fund, either wholly or in part, our purpose-built R&D facility and our manufacturing site, Silver One, in Belgium, our innovation lab in California, the establishment of our Volition Veterinary subsidiary, various R&D programs, and most recently, our Centers of Excellence program for Nu.Q NETs in Europe. Subsequent to quarter end, a Walloon institutional fund and regional government bodies of the Walloon Region of Belgium approved providing additional funding to the company, aggregating approximately $6 million. We are also expecting further amounts from other Belgian agencies to be secured in the first quarter of 2024. We would like to publicly thank the various government agencies in Belgium for their continued support. We have also greatly expanded our efforts with respect to seeking non-dilutive funding in the U.S. Our aim is to fund some of our major programs through either non-dilutive or project financing, which we anticipate could potentially be upward of $25 million over the next two years. Cameron will outline this strategy to fund our pillars going forward later in his portion of the call. Looking ahead, we also expect to receive a further $13 million in milestone payments from the Heska Corporation. Clearly, these are challenging times at a macroeconomic level. However, I believe that we are well-placed with our existing capital and expected near-term incoming funds to execute the plan the team have in place for this final quarter and into 2024. And with that, I will pass over to Dr. Tom Butera, CEO of our Volition Veterinary subsidiary. Tom? Thanks very much, Terig, and good morning, everybody. I am pleased to report that in the first nine months of 2023, revenue for the Nu.Q Vet Cancer Test grew almost five-fold over the comparable prior year period, reflecting sales of the reference kits through our global, regional, and local supply agreements. The revenue growth demonstrates solid progress to date, and we certainly expect more growth to come as additional companies fully launch our product, both in the U.S. and around the world. As you will have seen in a recent announcement, our Nu.Q Vet Cancer Test is now available in the U.K. Indeed, I am taking this call from London, England, as the team is in town for the London Vet Show over the coming days. We were thrilled the launch of our Nu.Q Test was featured in an article of the Sunday Times, one of the flagship papers here in the U.K. Really terrific exposure. The London Vet Show is Europe's largest veterinary exhibition, with more than 20% of U.K. vets attending the event. So we are looking forward to a busy few days, not only in the exhibition hall, but we also have a series of sponsored and invited talks on Friday with Dr. Sue Ettinger and Dr. Becca Timmons. There are 11 million pet dogs in the U.K., with 29% of the households owning one or more dogs, so we believe that the U.K. market provides another tremendous opportunity to drive access to our early detection test. We are delighted to be supplying two of the leading veterinary diagnostic providers in the U.K., Nationwide Laboratories and Veterinary Pathology Group, both of whom will also be promoting the Nu.Q Vet Cancer Test at the London Vet Show. We expect exciting times ahead on this side of the pond. We are also making progress in our efforts to provide greater access to our Nu.Q Vet Cancer Test in Asia, and we'll be launching with Vita Genomics in early 2024 in Taiwan, and also anticipate announcing a launch in the early part of 2024 with a leading veterinary diagnostic provider in Japan. In terms of our global licensing and supply agreements, IDEXX continues to ramp up the availability of the Nu.Q Test across the extensive U.S. Reference Laboratory Network. IDEXX is gearing up marketing efforts to drive awareness and trial of the product with U.S. conference season just around the corner in January and February 2024. The Mars Heska group continues to make very good progress as well, and we hopefully anticipate the launch of their exclusive point-of-care test very soon, which would also trigger a milestone payment to us. From a research and development perspective, under the guidance of Dr. Heather Wilson-Robles, Dr. Justin Hynes, and Dr. Becca Timmons, we are continuing to develop our feline product and will be expanding our Nu.Q platform into emergency medicine, specifically looking at NETosis, and I certainly look forward to bringing you more detailed updates on these two topics in the future. That's a quick update from me, given our packed agenda today. I will now, with great pleasure, hand over to Dr. Andrew Retter, a hematologist and intensive care consultant at one of the U.K.'s leading hospitals. Dr. Retter has provided invaluable insights and guidance to the Volition team and presented at our Capital Markets Day earlier this year, and at a number of informative webinars events the team has hosted. Dr. Retter will be providing his view on our progress with Nu.Q NETs, as well as discussing Volition's breakthrough method in early cancer detection. Andy, over to you. Thanks very much, Tom, for that introduction, and good morning, everybody. I'm delighted to join the call today and provide an update on some of the significant progress made with Volition's Nu.Q NETs and cancer pillars. So starting first with Nu.Q NETs and sepsis, which is how I first was introduced to Volition. Sepsis, as you've heard me say before, is one of the leading causes of death worldwide, with almost 50 million cases annually, leading to, unfortunately, around 11 million deaths. There is ongoing discussion about the diagnosis and definition of sepsis. Volition has made significant progress this quarter, which has carried through into the fourth quarter. In September, we hosted a key opinion leader roundtable event in Athens, Greece. This workshop, held over the course of two days, focused exclusively on sepsis and the potential role of Nu.Q NETs. It was attended by some of the world's leading experts, including three authors of the highly influential and critical Sepsis-3 clinical definition paper. The current chair of the International Sepsis Forum and the current chair of the European Sepsis Alliance, and many other attendees, are operating as a center of excellence within the Nu.Q NETs program, and so have first-hand experience with the assay. We desperately need new diagnostics and new tools to measure the progression of sepsis, and this may lead to new therapeutics. The sense from the group was that Nu.Q NETs potentially represents one of the biggest breakthroughs in sepsis and the management of sepsis in the last 40 years. If you would like to find out more about the KOL meeting, a short report was issued and is available in the download section of the Volition website. Moving forward with this group, I'm now working on a clinical review article with the intention to submit it for peer review and publication in the first quarter of 2024. Speaking of publications, shortly after the event and subsequent to quarter end, in October, the first clinical paper from the Center of Excellence was published. This was published by Professor Guillaume Monneret's group from Lyon. The data published demonstrated a mortality signal, so the higher the score, unfortunately, the more likely a patient is to die. It also confirmed the correlation with Nu.Q NETs and the SOFA score. The SOFA score is the current, but a little cumbersome, aggregate score used to diagnose and monitor sepsis. It is mainly used in research trials as opposed to day-to-day practice at the bedside. As a clinician, the reason for the high level of interest, and dare I say, excitement about the results with Nu.Q NETs, are that if we could establish a baseline and continue to monitor a patient with a simple blood test, this would be much more straightforward and more efficient than current practices. It also potentially provides us with a new therapeutic target to improve the care of our patients in the future. It is fantastic to have this first paper out, and we look forward to further data being published by Centers of Excellence in 2024 and beyond. Over in the U.S., I am pleased to report that Volition recently completed the Q-Sub process with the U.S. Food and Drug Administration. I am happy to announce that they have agreed the regulatory pathway of a traditional 510(k) path with an adjudicated clinical comparator. The Volition team is grateful for the opportunity to participate in the Q-Sub process and greatly appreciate the feedback from the FDA. These interactions were engaging and helpful, and Volition feels that such discussions gave it a clear regulatory path to follow for what we hope is an exciting opportunity. Finally, from a Nu.Q NETs perspective, I'm happy to say that the study at my own hospital, Guy's and St Thomas' NHS Foundation Trust in London, is about to open. Guy's and St Thomas' is sponsoring the study, and it is funded by Volition. As a reminder, this is a large-scale, 500-patient prospective study, which will run over the course of the next 12-18 months. It is fantastic to be up and running ahead of the winter months. I'd like to take just a few minutes to discuss Volition's potentially breakthrough cancer detection method presented at ESMO 2023, the annual congress of the European Society of Medical Oncology. For those with a particular interest in this topic, might I direct you again to the Volition website, where you can view a recorded webinar about this exciting breakthrough. Cancer, as we all know, is a deadly disease, causing around 10 million deaths a year. It is also set to grow as our population ages, with estimates of 13 million new cases a year by 2040. Like many diseases, early diagnosis has a significant impact on outcome. Putting it simply, the earlier we can diagnose cancer, the greater chance of survival and a good quality of life for our patients. Early diagnosis is challenging. Cancer develops silently with few symptoms, and so frequently people are diagnosed late when there are few treatment options available, or when treatment is available, it is more invasive and more aggressive. Indeed, in the U.K. where I work, about 45% of cancers are diagnosed at stage three or stage four. In early-stage cancer, it is difficult to detect cancer-derived circulating tumor DNA, so-called ctDNA. ctDNA in the blood may compromise only 0.01% of the DNA present around a background of 99.99% cell-free DNA circulating. Moreover, most of the cancer DNA has exactly the same sequence as normal DNA. Current ctDNA detection methods on the market and in development involve DNA extraction, sequencing of all the DNA in the sample, both cancer and normal, and analysis of the sequencing data using sophisticated computer bioinformatics to tell them apart. Volition has developed a novel method for liquid biopsy, involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood. These cancer-derived ctDNA fragments are then extracted after removal of all normal background DNA from the test. This allows detection with a simple, low-cost polymerase chain reaction. Volition's proof of concept data was presented at ESMO 2023 and demonstrates the isolation of tumor-derived DNA fragments from plasma. Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including early stage 1 disease. For example, 74% of leukemias were detected at 96% specificity, and 77% of colorectal cancers were detected at 92% specificity using ctDNA and PCR assays. These early assays were developed using leukemia as a model to follow. Surprisingly, we also detected many other cancers, including colorectal cancer, in a blood test with an accuracy approaching that of the current fecal immunochemical tests. As Dr. Jake Micallef, Volition's Chief Scientific Officer, known to many of you on the call today, previously stated, the results to date are exciting and pave the way for a whole new class of undiscovered biomarkers, with potentially hundreds of thousands of possible targets. Volition is now developing a range of cancer-specific assays, which it expects to be more accurate, both more sensitive and more specific than these preliminary results. And we really look forward to sharing progress in the beginning of the first quarter of 2024. In drawing to a close, I'd like to express my own personal excitement about the progress of the company, both through Nu.Q and with respect to its recent potentially breakthrough cancer detection method. I believe that Volition's technologies will not only help with diagnostic enrichment, but also with monitoring a patient's disease progression and response to treatment. Most incredibly, accomplishing these goals with what should be a relatively low cost, routine blood test, allowing it to be used around the world in multiple healthcare settings. Thank you very much for listening today. I will now pass you over to Cameron Reynolds for his final remarks. Thank you, Cameron. Thank you very much, Dr. Andrew Retter, for providing those insights, and thanks as always, to Tarek and Tom for their reports. It's a real sign of the varied expertise we now have at Volition. 2023 thus far has certainly been transformational for Volition. But before I reflect on that, I'd like to take a moment to elucidate our financial strategy. Given the current macroeconomic conditions, we are focusing on getting each pillar to support itself, either through product revenues, milestone payments, out licensing, or other non-dilutive funding by the end of 2024. We are currently targeting the following: We expect Nu.Q Vet to be overall cash flow positive from now on, through milestone payments and the expected revenue ramp as more partners launch and our existing partners expand into new territories. We expect Nu.Q Discover to more than double revenue in 2024 and to become profitable starting in 2025. We're running out of time to cover Discover separately on this call, but overall, we are very happy with progress, with nine contracts signed already and a further 10 currently in negotiation. Thirdly, we have begun a strategy to fund, as Tarek alluded to earlier, our Nu.Q NETs pillar through non-dilutive and/or project funding of up to $25 million. We have targeted a range of government agencies in the U.S. and Europe, and are also preparing the background work aimed at attracting a large player to either out-license or invest in the product directly. Four, lastly, as discussed by Gaël Forterre, our Chief Commercial Officer in our recent webinar, there has been a lot of external interest in our CTCF and Nu.Q Cancer technologies. Our strategy is to license this out to one or more larger companies, as a commercial undertaking of this size is likely beyond our current capabilities. If successful, we believe this strategy could provide us ongoing royalties and very meaningful milestone payments in 2024. Given the current macroeconomic conditions, we believe these methods of funding the four pillars should provide us a very good basis to move forward. To date, in 2023, the commercialization of our transformational Nu.Q Vet Cancer Test within the companion animals healthcare sector, has signed up several large new players, with more to come. Given the ongoing bedding in of our existing partners and the expected launch very soon of a range of others, we strongly suspect we will see very good revenue growth from Nu.Q Vet through 2024. I'm also delighted in the progress we made in our Nu.Q NETs pillar, and in particular, in determining our regulatory pathway forward with the U.S. FDA, a key milestone for the company. Thirdly, I'm absolutely delighted with the breakthrough CTCF cancer detection method, which we published just last month at ESMO. This is based on 13 years of work on the chemistry of circulating chromatin fragments. We have developed what we believe is a transformational wet chemistry pathway that identifies and physically isolates chromatin fragments that we know are tumor-derived from background DNA of the same sequence, and then tested with a simple PCR panel to establish whether cancer is present. A true breakthrough moment. The first reported physical isolation of tumor-derived circulating DNA fragments from blood. We believe that this method obviates expensive and time-consuming DNA sequencing and bioinformatics, allowing for rapid, cost-effective detection in a routine blood test. This has been a fantastic achievement by our research and development team, and one which has kept the intellectual property team very busy. As you can imagine, we believe that this represents a tremendous opportunity, a paradigm shift, as it were, for cancer detection, and indeed, from this preliminary data, early cancer detection. This method could become a must-have technology for everyone in the liquid biopsy space. Given its significance, we are very much open to licensing this technology. We have been very encouraged by the level of interest thus far from a range of different companies, and at this stage, nothing is off the table. Exclusive, non-exclusive, global, regional, cancer-specific or pan-cancer use. Exciting times, and this is exactly what we hoped for when we founded Volition. And so to sum up, I know it has been a long road to getting to where we are today, and I'm very proud of the progress we are making as a team at Volition, and that we have stuck with it and got to where we are today. It's an exciting time for us as a company, and we look forward to sharing further updates and milestones with you over the coming quarters as we continue to adapt to the changing times and conditions, to deliver on what we believe to be revolutionary technologies. In drawing this earnings call to a close, I'd like to thank you all for joining the call today. We very much appreciate it, given how much there is to digest across all of our pillars. We're happy to answer your questions now. Operator? Thank you. We will now conduct a question- and- answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in a question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Once again, that's star one to ask a question at this time. One moment while we poll for our first question. Our first question comes from Ross Osborn with Cantor Fitzgerald. Please proceed. Hi, everyone. Congrats on the progress, and thanks for taking our questions. Thank you. Just wanted to focus on Nu.Q Vet today, given it's the most near-term revenue opportunity. With regards to the U.K. market, how much coverage do you think the two reference laboratories have there? Yeah, great question, Ross. Thanks for asking it. I think we're gonna have broad coverage through the U.K. Both of these labs, Nationwide, and VPG, have extensive coverage in the U.K. throughout, and also VPG also has penetration into Ireland. So the answer to your question, quite simply, is broad coverage. Okay, great. And then maybe, turning to IDEXX, would you remind us the go-to-market strategy there, just in terms of marketing reach and current capacity? Yeah. IDEXX obviously is both a domestic U.S. company and has tremendous international exposure as well. They're currently... We've been working with them over obviously the course of their launch since January at VMX. And they are highly engaged with us at the current time. They are obviously an extremely large company, a lot of moving parts. We had some early hiccups in the reference labs initially, which we have now smoothed out, and they're working very well. And also we are extremely engaged with them in terms of collateral support and collaborative support on their educational awareness. And they are planning expansion in both domestic- both domestically as well as internationally in 2024. So we really, quite frankly, even though the ramp has been a little bit slower, one has to realize this is a new concept and a new discipline that's being brought to veterinarians, cancer detection. But they are highly engaged with us, and we anticipate a significant ramp-up over the course of 2024. Okay, great. And then last one, and I'll jump back in the queue. You mentioned your intention to commercialize in Japan and Taiwan in 2024. Could you just walk through the rationale for targeting those geographies specifically? Yeah, to give you an idea, well, first of all, Japan, we're talking about a companion animal market of over 22 million dogs and cats. A pretty significant number. I mean, we're talking in the U.S., 84 million. So that's a pretty large number compared to the U.S. In Japan, we're talking about 11,000 hospitals. In the U.S., we're talking about 26,000 hospitals, just to kind of give you some reference points. ...And then we have Taiwan, who's quite frankly, grown 49% growth in their companion animals over the last four years. And they're up to somewhere over 2 million pets, dogs, and cats in the current market right now, with about 1,600 veterinary hospitals. So I think between those two, giving you some numbers and comparing them to the U.S., you can see they're very nice opportunities for us and considerable potential expansion for us in both those countries. Thank you for taking our questions. Congrats again. Thanks, Ross. Thank you. Have a great day! The next question comes from Bruce Jackson with The Benchmark Company. Please proceed. Hi, good morning, and thanks for taking my questions. Thank you. So, just a couple of cash flow questions. First, on the payment from Walloon, is that gonna hit in the fourth quarter? And then, how much of that goes on the cash flow statement, and how much goes to the income statement? Good question. It will all go to the cash flow statement. It's cash that we will get in the next month. We're also expecting more from a national-level body in Belgium, probably early Q1 next year. But these are in the form of funding similar to what we've had before, where we've had $19 million of funding from the Walloon Region in Belgium. That's a combination of grants and soft loans, and that's helped us to finance a lot of the operations, including our Silver One production facility in Belgium. And yeah, we're very grateful for the support that we've had from Belgium and the Walloon Region. Okay, and then, same question for Heska. What's the timing and the amount of the milestone, and then how does that flow through the income statement? So the milestone will occur when Heska launches the product. How that flows through the income statement, it's a milestone payment, so similar to the first one that we received. We received $10 million upfront, if you recall that. That goes onto the balance sheet as a deferred income and is then earned out as we make future sales. But as before, we could use them all immediately on arrival, if you will, for the company. Cool. They're all very much part of our working capital. It's all cash in the bank, so you'll see that cash on the balance sheet. And it's available to us when we collect it. Okay, great. And, Bruce, if you add it all up, with the two the amounts we expect from the regional funding and the Belgian funding, as well as those milestone payments on the launches, you're looking well into the $20 million range, over $20 million. So obviously, a very big part of the money will need to get the milestones reached next year. Yeah. Perhaps I can add to that. You know, with that funding, with the milestones, with the money from Belgium, with what we've got currently, we do have line of sight on funding from the end of Q3 through the next 12 months. Okay, super. Last question on the CTCF research. I think you mentioned during the last webcast that there'd be some more data coming out during the first quarter. Is that still the case? Yes, absolutely. So obviously, it was very good preliminary data, and we've had a lot of interest from partners, which, we're very excited about, and it, it is bigger than us, so, we're very excited. But of course, we're working all the time, not only on more data, which is obviously very important in a range of cancers, which we aim to be presenting at, specific conferences for those cancers, as well as we're working on the, it has not been optimized at all. So we're going through all the things to optimize it, to make it as simple and easy and as routine as possible. And also, the optimizations, should also help with the, overall accuracy. So overall, I think, as you know, Bruce, I'm a very optimistic person, but I'm very, very happy and a little surprised how quickly it's actually gone, even since ESMO, with the level of interest. Jake's at a conference next week, the Liquid Biopsy Conference, also in Madrid. So we're talking to a lot of other potential partners there. So expect to see a lot of information through this year and into next year, and data, as we said, in Q1. All right, great. Thank you for taking my questions. Thank you. Have a great day, Bruce. Our next question comes from Tim Moore with EF Hutton. Please proceed. Thanks. For new investors joining this call, maybe can you provide some anecdotes on how vets find your testing kits exciting and useful and conveying that excitement to canine dog owners? You know, can you give any kind of interaction anecdotes or color behind that? You know, it's a rapid outcome test, but, you know, vets seem to be buying into the adoption of the early cancer detection and probably spreading the word. I mean, any sense of vet awareness for this rapid testing of cancer? You think, like, a third of vets know about it already? Yeah. Thank you, thank you for the question. As I mentioned earlier in the call, early cancer detection is a new test, and a new area of involvement for my veterinary colleagues. We are obviously going around the world in terms of conferences, where we're speaking to both general practitioners as well as oncologists. ... and also obviously spending a lot of time in the U.S. going to major meetings. So what we're actually doing, there is robust interest in the cancer screening test, and they are learning from us as well as our partners on how to use the test and how to communicate it to the clients, and how to bring it into their normal workload and normal exam room patterns when they interact with their clients and their pet owners. So consequently, the interest is significant. We're spending a lot more time on how to use the test now and how to communicate it, and then what to do after you get something that comes back normal. But so you know, the overall message with a screening test is one of peace of mind, 'cause close to 92% of the dogs are going to come back in a normal range, and you have 6%-8% potentially that are in a higher range. But unfortunately, in the United States, where 6 million dogs a year develop cancer, it's a large number. So overall, the education continues with IDEXX, with our partners, with Heska, and also with my own team, the vet team here at Volition, and that is an ongoing thing that we will continue to do throughout 2024 and 2025. But the interest has been robust. The use is increasing dramatically, and we're very excited about how our veterinary colleagues have received it. That's great color. I appreciate it. My next question is about Heska and the milestone payments to possibly be received over the next several months. You know, is it fair to just assume that, you know, with any companies that get taken over, like the Mars takeover, you know, that might have slowed it, slowed it down, the milestone payment. But is it possible that Heska could maybe launch both screening and monitoring at the same time, so you can get a double milestone payment? Yeah, I think that's a great question. To answer the first part of the question, with reference to the acquisition of Heska via Mars, that really, quite frankly, hasn't slowed down the optimization process that we've been doing on the point of care. As I mentioned in my earlier comments, you know, on the video that we had done today, we're talking about a tech transfer going from a reference lab test to a point of care test, which is something that my veterinary colleagues use in their veterinary hospitals. It is a major accomplishment to do something like that, and consequently, it has taken some time to do it, and it's gone a little bit longer than we anticipated. But we're almost there, and at the... When you think about it, from a 12-month period of time when this was started to where we are now, it's a tremendous accomplishment. We were getting very close to a launch. So that point is, well taken and hopefully understood. That's helpful. My last question- Could I, could I do them together, both screening and monitoring? Yeah. The second part about screening and monitoring, since I've been in the field of veterinary medicine for a number of years, what you really want to do is you want to make sure that you're getting your message across to the colleagues on not too many things at the same time. You know, we want to be very clear on our Nu.Q cancer screening test, which is our first test, and make sure they're using it, using it effectively, and that is the direction we're going in right now. And obviously, it's out there, and thousands of tests have been run at this point in time, and we'll continue to do that. We will be entering the market with our monitoring application. We already have a peer-reviewed paper that came out in May 2022. We are talking about it with our colleagues extensively, but we don't want to mix, confuse the message. We anticipate that the monitoring application will probably really be introduced, probably more like in the first quarter of 2024. And yes, to your point, will we get kind of a double with that between the screening and monitoring? Of course, because both of those tests will interact with each other, and it will obviously bring even more credibility to both screening as well as monitoring. But we're focused on the screening first, and now we're continuing our education of the doctors on the monitoring, and that will follow suit after that. Great. That, that's helpful. My, my last question is just: What do you think might be the timing, timeframe of the Feline test launch? Is that more of December next year? And can you remind me if, you know, when that does occur, is that... Does that trigger a $5 million milestone? Yeah. The Feline test right now is in its pre-analytic stage. We're going through pre-analytic studies right now, and then we're going to go through more clinical studies in 2024, early part of 2024. We'll be producing a paper on it by the first half of 2024. And then, the anticipation is and the hope is that we will have a cancer screening test coming out of it that we can utilize in probably, hopefully the second half of 2024. Once that is there, that should trigger a payment from Heska with reference to the Feline program and, particularly with reference to cancer in the cats. Great. Thanks. That's it for my questions. You're welcome. Thank you. Come back then. The next question comes from Kyle Haycock with Saxo Investment. Please proceed. Hi, good morning. Just a quick question on the R&D expenses. They were lower in the third quarter than the first and second quarters of 2023. Do you think that was due to the winding down of the U.S. clinical activities or the expense rationalization program, or was it some other factors? As I think we've mentioned, we've had about $1 million of cash expenses in the quarter related to the DEXA studies for the sepsis trial in the U.S. Yeah, we don't - we won't see that in the next quarter because those are now wound down. We have begun to see some savings from the rationalization program. But, you know, in our business, expenses are pretty lumpy. It's very difficult to see smooth trends from one period to another. But, what I can say is, you know, in terms of the underlying cash burn, we do expect that it's gonna come down a little bit, from here on. Great. Did I answer? Yes, thank you. And then, just another quick one. At ESMO, I think you started to see some clinical results from the efforts from the National Taiwan University. Do you know when you might expect some results from the U.S., the IDEXX study? The process for the lung side has been quite active on, on both fronts. So we've wrapped human oncology together with the transcription factors, and the actual data itself, I can get back to you. What's the timing again? It's Louise Batchelor here. In terms of the paper, the paper's now being written up by the National Taiwan University Group, led by Professor Chen. So they're working on a clinical paper that will then be submitted for peer review and publication. And then what we're looking to do, from a lung cancer point of view now, in terms of that specific application, is a validation project, which is likely to be done in another market. But we haven't yet finalized that study in order to announce that. Of course, there are a lot of results coming out of France as well, and we expect the first clinical use of Nu.Q in human oncology to be in France early next year in lung cancer with Dr. Payen's facilities. So it's made progress, and I think, I think something we should reiterate quite a lot as well, the transcription factor is incredibly exciting, but Nu.Q platform itself is still very much part of what we do. Very active in the vet space, of course, but also it has still a strong place in the human space. So human oncology will be a strong mixture, I think, of our Nu.Q platform and the transcription factor platform going forward. Thank you very much for taking my questions. Thank you. Have a great day. The next question comes from Ilya Zubkov with Freedom Broker. Please proceed. Yeah, good morning, and thank you for taking my question. Congrats with progress in the quarter. Thank you. Could you share any details on the expected regulatory path on Nu.Q NETs in the U.S.? What steps are left to go through the, to go through to get FDA clearance for it? Yes, absolutely good, good question. So of course, we've been very active with the FDA. And just starting off, it's very exciting to, the rubbers hit the road, if you will. To be in such active discussions with the Food and Drug Administration is a very exciting milestone for us. So obviously, we submitted a process, and what we discussed last time is we're keen to either get a breakthrough designation status or a clear path through a 510(k), which is potentially a, a very, a clear path. And as we talked about, we're very happy to say we do have a clear path now. The path itself is the 510(k) path, and that takes, depending on the process and what data you need, but usually about 2.5 years from start to finish to get FDA approval. And obviously, I discussed a lot, we understand the conditions we're in now, in the macroeconomic environment. So we're looking to fund projects, so that we don't, we can limit to a very minimum any dilution from from the top company. So we're working on ways to finance the NETs process. Obviously, we've had a lot of Belgian assistance, and we've had some more coming through. We're also looking for similar funding in the U.S., and also looking to package up this to get a large diagnostic companies or one of the large diagnostic companies perhaps interested in sharing the development costs to get through the FDA. So we have a very clear path now, which is exciting, and we will be pressing the button once we're comfortable with the funding routes to get us where we need to get to. And in Europe it is actually salable now, as you're probably aware, through our IVDD approval. So now we're doing market studies for marketing studies, if you will, to get adoption for clinical utility. So that'll be coming out. And we're also looking for a group to help fund the IVDR, which is the longer-term European approval process, which is now taking over. So overall, we have a very clear path in Europe and in the U.S., and but we're just very mindful, we don't want to start spending a lot of money until, we've allocated the finance for it in as non-dilutive fashion as humanly possible, and that's what's in the process now. So we should have a lot more information on that through the year. But the bottom line to your question is about 2.5 years from when we press that button for the FDA. Great. Thanks a lot. Thank you. Have a great day. Thank you. At this time, I would like to turn the call back to management for closing remarks. Thank you, everyone. There's a lot to be taking in at the moment. There's a tremendous amount going on in the company, and I think as you've probably taken from everything we've said, we're tremendously excited with all of the pillars now, which are really coming through. But of course, in this environment, that excitement is tempered with the knowledge that we have to be very careful with our capital, which we have been. We have a line of sight to a lot of incoming money, which we've talked about. We're also pushing for as many other ways of funding what we do with as well as possible, non-dilutively. So we'll have a lot of information through the rest of the year. So we're looking forward to hopefully what's looking to be a strong vet ramp through next year, as well as the other exciting breakthroughs that we have. So thank you very much for your time, and I'm looking forward to speaking to you all soon with updates in all of our pillars. Thanks for your time. Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation, and have a great day.